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Two-component signaling systems involving receptor-histidine
kinases are ubiquitous in bacteria and have been found in yeast
and plants. These systems provide the major means by which
bacteria communicate with each other and the outside world.
Remarkably, very little is known concerning the extracellular
ligands that presumably bind to receptor-histidine kinases to
initiate signaling. The two-component agr signaling circuit in
Staphylococcus aureus is one system where the ligands are
known in chemical detail, thus opening the door for detailed
structure–activity relationship studies. These ligands are short
(8- to 9-aa) peptides containing a thiolactone structure, in which
the a-carboxyl group of the C-terminal amino acid is linked to
the sulfhydryl group of a cysteine, which is always the fifth
amino acid from the C terminus of the peptide. One unique
aspect of the agr system is that peptides that activate virulence
expression in one group of S. aureus strains also inhibit virulence
expression in other groups of S. aureus strains. Herein, it is
demonstrated by switching the receptor-histidine kinase, AgrC,
between strains of different agr specificity types, that intra-
group activation and intergroup inhibition are both mediated by
the same group-specific receptors. These results have facilitated
the development of a global inhibitor of virulence in S. aureus,
which consists of a truncated version of one of the naturally
occurring thiolactone peptides.
S taphylococcus aureus infections are a major cause of mor-bidity and mortality in community and hospital settings.
Consequently, the emergence of methicillin-resistant and,
more recently, vancomycin-resistant strains of S. aureus rep-
resents an enormous threat to public health. S. aureus patho-
genesis primarily involves the secretion of toxins that damage
or lyse host cells or interfere with the immune system, enzymes
that degrade tissue components, and cell wall-associated pro-
teins that may be involved in adhesion and protection against
host defenses. Synthesis of many of these virulence factors is
controlled by a global regulatory locus, agr (1, 2). This locus
contains a two-component module that is activated by a
secreted autoinducing peptide (AIP) in a cell density-
dependent manner. This type of regulation falls under the
rubric of the ever-broadening field of quorum sensing (3),
whereby a population of bacteria responds in concert when a
critical cell density is reached. In the case of S. aureus, as cells
enter postexponential phase, the AIP reaches a threshold
concentration that turns on the agr (virulence) response. This
process is mediated by the five genes in the agr locus, agrB, D,
C, A, and rnaiii (Fig. 1). The P2 promoter drives the tran-
scription of the agrB, D, C, and A genes, which provide the
cytosolic, transmembrane, and extracellular components of a
quorum-sensingyautoinduction circuit. The agrD gene product
is a propeptide that is probably processed and secreted by
AgrB, an integral membrane protein (4). The resultant mature
AIP binds to the transmembrane receptor-histidine kinase
coded by agrC. Binding of the AIP triggers phosphorylation of
AgrC on a histidine residue. The response regulator, AgrA,
accepts the phosphate group from AgrC and, in conjunction
with a second transcription factor, SarA (5, 6), activates
transcription from the agr P2yP3 promoters. The P3 transcript,
RNAIII, mediates up-regulation of secreted virulence factors
as well as down-regulation of surface proteins (7–9).
The AIP–AgrC receptor pair shows considerable interstrain
sequence variation, which must have resulted from evolutionary
covariation of this region of the chromosome to retain the
specificity of the receptor–ligand interaction. S. aureus strains
can be divided into at least four agr specificity groups (10, 11).
These strains appear to compete with each other at the level of
agr expression, as each AIP inhibits the agr response in strains
belonging to other groups. This type of bacterial interference is
unusual, because it affects the expression of a subset of genes
rather than inhibiting growth (10). Because of the intergroup
inhibitory effects of the AIPs, we are now redefining ‘‘AIP,’’ an
acronym for ‘‘autoinducing peptide,’’ to mean the mature AgrD
peptides and their synthetic or modified variants. This usage is
irrespective of whether the AIP acts as an autoinducer or as an
inhibitor of agr expression.
Structure–activity analysis of the AIPs from S. aureus has
begun to elucidate their mechanism of action (10, 12). These
peptides contain a thiolactone ring structure (10) in which the
a-carboxyl group of the C-terminal amino acid is linked to the
sulfhydryl group of a cysteine, which is always the fifth amino
acid from the C terminus of the peptide (see example in Fig. 1)
(12). There are usually three or four amino acids N-terminal to
the cysteine, which are collectively referred to as the ‘‘tail’’ of the
AIP. The high-energy thiolactone linkage appears to be neces-
sary for activation; the corresponding lactone and lactam ana-
logues of the Group II AIP are inactive, as is the linear version
of this and other AIPs (4, 12). However, the lactam and lactone
analogues (but not the linear version) are potent intergroup
inhibitors, arguing that the high-energy thiolactone linkage is not
required for intergroup inhibition, but that the ring structure is
important for both types of activity. It has also been shown in a
murine s.c. abscess model that the Group II AIP attenuates the
virulence of a Group I strain, which suggests possible therapeutic
value for the AIPs (12). Agr is conserved throughout the
staphylococci, and studies of the Staphylococcus epidermidis
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AIPs have generally confirmed what is known for S. aureus
(13, 14).
There are two remarkable features of this system. First, the
AIPs show major sequence diversity yet explicitly cross-inhibit
agr activation with IC50s that are in the same range as the EC50s
of the cognate AIPs. Second, analogs with oxygen or nitrogen in
place of sulfur in the ring structure (i.e., the lactone or lactam vs.
the thiolactone) are potent intergroup inhibitors, but neither
activate nor inhibit their cognate receptors, at least when tested
at concentrations a hundred-fold higher than the activating and
inhibiting concentrations of the natural ligands. In earlier studies
(4, 10, 12), agr activation and inhibition were studied in strains
containing the chromosomal agr locus, sometimes by using a
plasmid-carried agrP3::b-lactamase (blaZ) reporter. In these
studies, the endogenous peptide was produced and its concen-
tration varied over time, which made precise studies of activation
and inhibition difficult. Furthermore, the experimental design
precluded the separation of the agr locus from any other possibly
group-specific factors that might have a role in inhibition or
activation. In the present study, we demonstrate that the group
specificity of the response to the AIP (inhibition or activation)
is, in fact, determined solely by the AIP–receptor interaction. In
other words, AIP-specific inhibition as well as activation occurs
at the level of the receptor, AgrC. These results have led to the
development of a variant AIP that inhibits autologous as well as
heterologous agr expression and is therefore a global inhibitor of
the virulence response in S. aureus. This variant, a truncated
Group II peptide lacking the tail, is proposed to act by inter-
fering with AIP binding to the receptor.
Materials and Methods
Bacterial Strains and Growth Conditions. Bacterial strains used are
listed in Table 1. S. aureus cells were grown in CYGP broth (15)
with shaking at 37°C. Overnight cultures on GL plates (15) were
routinely used as inocula. Cell growth was monitored with a
Klett–Summerson colorimeter with a green (540-nm) filter
(Klett, Long Island City, NY) or a THERMOmax microplate
reader (Molecular Devices) at OD650. Antibiotics used were
ampicillin (100 mgyml) for Escherichia coli and erythromycin (10
Fig. 1. The agr locus is depicted, showing the various components and their
putative actions in the signaling network.
Table 1. Strains and plasmids
Strains or plasmids References Comments
S. aureus
RN4220 15 Mutant of 8325-4 that accepts foreign DNA
RN6390b 15 Group I prototype
RN6734 15 Group I strain, f-13 lysogen of 6390b
RN6911 8 Group I RN6390b, with tetM replacing agr (agr-null)
RN7206 8 Group I prototype, RN6734, with tetM replacing agr
RN6607 10 Group II prototype
RN9120 Unpublished Group II with tetM replacing agr (agr-null)
RN8465 10 Group III prototype
RN4850 Unpublished Group IV prototype from University of Minnesota strain KG*
RN9121 Unpublished Group IV with tetM replacing agr (agr-null)
RN9033 This study RN6911 with pRN7035
CA1-I (RN9222) This study RN6911 with pRN7062
CA1-I (RN9365) This study RN7206 with pRN7062
CA1-II (RN9366) This study RN9120 with pRN7062
CA2-II (RN9372) This study RN9120 with pRN7105
CA2-I (RN9367) This study RN7206 with pRN7105
CA4-IV (RN9371) This study RN9121 with pRN7107
CA4-I (RN9380) This study RN7206 with pRN7107
S. epidermidis
RN2375 This study Clinical isolate
S. warnerii
RN3178 This study Clinical isolate
E. coli
DH5a Cloning strain
Plasmids
pRN7035 This study Vector containing only agr-P3<blaZ fusion
pRN7062 This study Vector containing group I agrCA and agr-P3<blaZ
pRN7105 This study Vector containing group II agrCA and agr-P3<blaZ
pRN7107 This study Vector containing group IV agrCA and agr-P3<blaZ
*Kindly provided by Dr. Patrick Schlievert.
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mgyml) and tetracycline (5 mgyml) for S. aureus. Biotyping of
staphylococci was performed at the Tisch Clinical Microbiology
Laboratory, New York University Medical School, which con-
firmed the species classification of the non-aureus strains.
Construction of Strains and Plasmids. A shuttle vector, pRN7035,
was used that contains plasmid replicons for E. coli and S. aureus
along with antibiotic resistance cassettes: ampicillin for E. coli
and erythromycin for S. aureus. This plasmid was constructed by
cloning a PCR product containing the 180-nt agr P2P3 region
into the pUC polylinker site of plasmid, pRN7034, which con-
tains a b-lactamase reporter gene. In the new construct, the P3
promoter is fused to the b-lactamase reporter gene. Plasmids
pRN7062, pRN7105, and pRN7107 were constructed by cloning
PCR fragments containing agrC, agrA, and downstream termi-
nation signals from the various groups, into the PstI or PstIySphI
sites of the pUC polylinker of pRN7035. Genomic DNA from a
prototypical strain of each group was used as template in these
reactions. The following PAGE-purified primers (Integrated
DNA Technologies, Coralville, IA) were used in the PCR
reactions: for pRN7062, forward primer, 59-CCAACTGCAG-
GAAGTACCAAAAGAATTAACACAA (PstI site under-
lined), reverse primer, 59-TTATACTGCAGACGTTTGC-
CAACATTACAAGAGG (PstI site underlined), for pRN7105,
forward primer, 59-TTTGAACTGCAGAAAGTACCCGCT-
GAATTAACG (PstI site underlined), reverse primer,
59-GGTGAAGCATGCAGTTTGCCAACATTACAAGAGG-
TTGAACAAGCATTTTAA, (SphI site underlined), for
pRN7101, forward primer, 59 TCTTAACTGCAGAAGTT-
GAAATACCTAAAGAATTAA CTCAATTACACG (PstI
site underlined), reverse primer, 59-GGTGAAGCATGCAGT-
TTGCCAACATTACAAGAGGTTGAACAAGCATTTTAA,
(SphI site underlined). Plasmid DNA from the corresponding E.
coli DH5a derivative was introduced into the restriction-
defective S. aureus strain, RN4220, by the protoplast method
(15). Plasmids were then moved onto various genetic back-
grounds by phage transduction (15). Note that RN9365 (CA1-I)
(Table 1) is an additional strain with Group I agrC and agrA in
a different Group I strain background. This strain was tested, and
the results for RN9222 (CA1–1) were reproduced in this strain.
Preparation of AIP-Containing Supernatants. S. aureus strains were
grown in CYGP broth with shaking at 37°C for 9 h starting with
an inoculum of ’3 3 107 cellsyml in 10 ml of broth. Cells were
removed by centrifugation at 4°C, and the supernatant was
filtered (0.22-mm filter, Gelman). The filtrate was stored at
280°C and used as a source of AIP. The group-specific activity
of each supernatant correlated with that of the corresponding
synthetic peptide.
Synthetic Peptides. All peptides used in this study have been
previously described (12), except for the Group II truncated
thiolactone peptide, Ac-Cys-Ser-Ser-Leu-Phe-CO, which was
synthesized by using the transthioesterification method (12).
After reverse-phase HPLC purification of the peptide, the
product was characterized as the expected N-acetylated thiolac-
tone-peptide by electrospray MS and two-dimensional 1H NMR
spectroscopy: observed mass 5 580.0 6 1.0 Da, predicted
(average) mass 5 579.7 Da; 1H NMR (400 mHz, DMSO-d6) ›
0.71 (Leu-4, g2CH), 1.07 (Leu-4, d2CH), 1.30 (Leu-4, b-CH),
2.79 and 3.17 (Cys-1, b-CH), 2.95 and 3.30 (Phe-5, b-CH), 3.61
(Ser-3, b-CH), 3.65 (Ser-2, b-CH), 4.08 (Leu-4, a2CH), 4.24
(Ser-2, a2CH), 4.27 (Cys-1, a2CH), 4.29 (Ser-3, a2CH), 4.67
(Phe-5, a2CH), 7.14–7.31 (Phe-5, Ar), 8.04 (Ser-3, NH), 8.18
(Leu-4, NH), 8.31 (Ser-2, NH), 8.34 (Cys-1, NH), 8.98 (Phe-5,
NH) ppm.
Agr Autoinduction and Inhibition Assay. Agr-null derivatives were
used with a plasmid containing a constant agr P2P3::b-lactamase
(blaZ) fusion plus a group-specific agrAC module. Assays were
performed with CYGP cultures in early exponential phase
(’2 3 108 cellsyml). Culture supernatants (1y10 volume) or
synthetic peptides in 10 mM phosphate buffer at pH 5.8 (con-
centration of stock solution determined by UV absorbance) were
added, and cultures were incubated with shaking at 37°C for an
additional 60 or 90 min, followed by determination of agr
activation by b-lactamase assay (4). For inhibition tests, the
activator and inhibitor were added simultaneously. EC50 and
IC50 values were calculated from the sigmoidal dose-response
curves by using nonlinear regression analysis with the program
PRISM (GraphPad, San Diego). All assays were performed at
least in duplicate.
Reverse-Phase HPLC Analysis of d2Toxin Levels. A modification of
the assay originally described by Otto and coworkers (13) was
used to quantify d2toxin in supernatants from various strains.
Early exponential-phase cultures were treated with increasing
concentrations of synthetic peptides and then allowed to grow
for 9 h. Supernatants, obtained by centrifugation, were analyzed
by reverse-phase HPLC on a Hewlett–Packard 1100 series
instrument with diode array detection. Typically, 400-ml aliquots
of supernatant were injected onto a 1-ml Pharmacia Resource
PHE column, which was eluted at 1 mlymin as follows: isocratic
at 35% buffer B in buffer A for 3 min, which allowed the majority
of the UV-absorbing material to wash through the column,
followed by a linear gradient of 35–50% B in A over 20 min,
where A 5 0.1% trif luoroacetic acid (TFA) in water and B 5
0.1% TFA in 90% acetonitriley10% water. This optimized
gradient achieved excellent separation of d2toxin from other
components (.95% pure by HPLC and MS), which permitted
direct quantitation by peak integration. d2Toxin is usually
N-formylated, and the additional 29 Da of the N-formyl group
was included in the calculated mass. We observed the following
masses on purified fractions of d2toxin: S. aureus Group III,
observed mass 5 3,007.1 6 2.2 Da, predicted (average) mass 5
3,006.5 Da; S. epidermidis strains, observed mass 5 2,848.7 6 1.5
Da, predicted (average) mass 5 2,848.4 Da, and Staphylococcus
warnerii strains, observed mass 5 2,900.1 6 0.8 Da, predicted
(average) mass 5 2,899.4 Da.
Results
Reconstitution of agr Signaling in agr-Null Host Backgrounds. Shuttle
vectors containing agrC and agrA under control of the agr-P2
promoter, along with a b-lactamase reporter gene driven by the
agr-P3 promoter, were introduced into agr-null strains (see
strains, Table 1). We reasoned, on the basis of prior studies (4,
10), that these constructs would be sufficient for signaling to
occur in the agr-null backgrounds in response to exogenously
added AIP. This was confirmed as shown in Table 2 and by
example in Fig. 2. Two strains were used in these experiments,
RN9222 (CA1-I) and RN9372 (CA2-II), containing the cloned
agrCAyb-lactamase in the corresponding agr-null S. aureus strain
(all reconstituted strains are provided with a descriptor in the
format CAx-y, which indicates Group x agrC and agrA on the
Group y agr-null background). In both cases, dose-dependent
activation of the agr response was observed on addition of the
cognate synthetic AIP (for example, see Fig. 2 A). Moreover, the
calculated EC50 values for agr activation in the two reconstituted
strains were similar (Table 2). No dose-dependent agr activation
was observed in the control strains, RN9033 and RN9416, which
contain the vector alone (for example, see Fig. 2 A).
Reconstitution of Cross-Strain Inhibition in the Absence of AgrB. As
previously demonstrated (10), S. aureus culture supernatants
inhibit agr activation in heterologous strains. Our prior study by
13332 u www.pnas.org Lyon et al.
using a reporter gene assay in strains containing the endogenous
agr locus (12) demonstrated that synthetic AIPs could reproduce
these effects. However, the site of action for the inhibition seen
with these peptides was not determined. Although the most
likely site seemed to be AgrC, the diversity of sequences among
inhibitory peptides and their analogs suggested that some mech-
anism other than competitive blocking of activator binding could
be responsible. One possibility would be binding to the putative
processing–secretion factor, AgrB, causing interference with
production or secretion of the activator. Alternatively, the
peptides could bind to any range of targets on or within the cells
and could interfere with the agr signaling pathway up- or
downstream of AgrC activation.
As shown in Fig. 2B, RN9222 (CA1-I) was grown with Group
I AIP at 100 nM along with various concentrations of the Group
II AIP. A dose-dependent inhibition response was seen with an
IC50 value of 90 6 30 nM (Table 2), thus demonstrating that
inhibition occurs in the absence of AgrB. Similar experiments
were performed with RN9372 (CA2-II), yielding an IC50 for
inhibition by the group I AIP of 26 6 7 nM (Table 2). These
results, in two different agr specificity groups, confirm that AgrB
cannot be the target of inhibition, as the new strains lack AgrB.
The agrAC Two-Component Module Is Necessary and Sufficient for
Group-Specific Activation and Inhibition. We next asked whether
AgrC determines the group specificity of the AIP response. This
question was addressed by testing the two-component module in
agr-null host backgrounds derived from different agr groups.
Transfer of the group-specific signaling phenotype with agrCA
would argue against any other group-specific determinant. Ac-
cordingly, two strains, RN9366 (CA1-II) and RN9367 (CA2-I),
were tested for their ability to respond to supernatants from agr6
strains, as well as to Group I and II AIPs.
The two strains were compared with the appropriate controls,
RN9222 (CA1-I) and RN9372 (CA2-II), for activation by post-
exponential phase supernatants from a series of agr6 strains and
by AIPs. As illustrated in Fig. 3, only supernatant from the
Group II agr wild-type strain, RN6607, was able to activate
b-lactamase expression in RN9372 (CA2-II) and RN9367 (CA2-
I). In addition, similar EC50 values for activation were obtained
for both strains by using Group II AIP (Table 2). Analogous
results were obtained by using RN9222 (CA1-I) and RN9366
(CA1-II): these were activated by wild-type Group I superna-
tants (RN6734) and not by Group II supernatant or by agr-null
Table 2. Activation and inhibition by AIPs and an AIP analog
RN9222 (CA1-I) RN9366 (CA1-II) RN9372 (CA2-II) RN9367 (CA2-I)
Activation EC50, nM
Group I AIP 40 6 9 23 6 7 — —
Group II AIP — — 34 6 6 28 6 14
Inhibition IC50, nM*
Group I AIP — — 26 6 7 135 6 52
Group II AIP 90 6 30 78 6 12 — —
RN9222(CA1-I)* RN9372(CA2-II)* RN8465(GroupIII)† RN9371(CA4-IV)‡
Inhibition IC50, nM for Group II AgrD truncated thiolactone
Group II AIP, truncated 272 6 67 209 6 39 10 6 1 188 6 50
All values include an error of 6SEM determined from at least two assays.
*These values were obtained with a constant concentration, 100 nM, of the autologous (activating) AIP.
†All results determined for the Group III strain RN8465 were from HPLC analysis of d toxin. All other results were from b-lactamase assays.
‡Group IV supernatant was used as a source of activating AIP in these analyses.
Fig. 2. Synthetic thiolactone peptides are biologically active in reconstituted
strains. Shown are representative data for activation (A) and inhibition (B) of
the agr response by synthetic AIPs. Degree of activity based on b-lactamase
activity is shown as a plot of Vinit (initial velocity) vs. peptide concentration. (A)
Activation of the agr response in RN9222 (CA1-I) by Group I AIP. The RN9033
(vector alone) control is shown. (B) Inhibition of the agr response in RN9222
(CA1-I) by Group II AIP in the presence of activating Group I AIP at 100 nM.
Fig. 3. A representative example of activation of RN9372 (CA2-II) and
RN9367 (CA2-I) by postexponential supernatants collected from Group 1, 2,
and 4 agr6 cells. Data were collected as b-lactamase activity (Vinit in mODymin)
and then normalized to percentage activation.
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supernatants from either group (data not shown). Moreover,
similar EC50 values for activation were obtained for both strains
by using the Group I AIP (Table 2). Therefore, the group
specificity of agr signaling does not depend on the host back-
ground. Furthermore, the conversion of an agr-null Group I
strain, RN7206 into a Group II responsive strain, RN9367
(CA2-I), by the insertion of plasmid-encoded Group II agrC and
agrA (and vice versa) suggests strongly that the group specificity
of the agr response depends on the expression of the two-
component module containing agrC and agrA.
The next question was whether cross-strain inhibition also
proceeds through the AgrCyAgrA two-component cascade. If
so, a Group II agr null strain (RN6607) reconstituted with Group
I agrC and agrA, i.e., RN9366 (CA1-II), should be inhibited by
Group II agr1 supernatants or by Group II AIP. Alternatively,
if inhibition were to involve a group-specific factor outside of the
agr locus, then inhibition would depend on the host background
in which AgrC and AgrA are expressed. The former alternative
was shown to be correct, as very similar IC50s for inhibition by
the Group II AIP in RN9366 (CA1-II) and RN9222 (CA1-I)
were obtained (Table 2). The same was true for inhibition of
RN9372 (CA2-II) and RN9367 (CA2-I) by Group I AIP, albeit
with a slight difference in the IC50s (Table 2). It is apparent that
inhibition by the AIP depends on which agrC and agrA genes are
expressed and not on the genetic background in which they are
expressed, thereby indicating that the site of inhibition must be
within the Agr A-C module. Because AgrC is a variable trans-
membrane receptor (16) and AgrA is highly conserved, it is
suggested that the inhibitors bind to and act at AgrC.
Synthesis and Testing of a Global Inhibitor of Virulence in S. aureus.
Previous structure–activity studies have identified key regions
within the Group II AIP required for differential agr activation
and inhibition (12). Changes in the ring structure of the AIP
could affect either activation or inhibition of the agr response or
both, whereas changes in the tail region of the molecule affected
only activation. We reasoned that a truncated AIP analog
containing only the thiolactone ring structure and lacking the
activating tail might be able to bind its own AgrC receptor,
because of conservation of the critical thiolactone moiety, but
would not have the tail necessary for activation. This analog
would therefore be a good inhibitor not only in a crossgroup
manner but also within the same group. Converting a receptor
agonist into an antagonist of its autologous group as well as an
inhibitor of heterologous groups would represent a global in-
hibitor of virulence in S. aureus. This would comprise a key step
in the development of an agr-based therapeutic.
A truncated Group II thiolactone peptide was synthesized by
using the transthioesterification approach (12) and tested for its
ability to activate and inhibit the agr response in Group I–IV
strains. The Group I, II, and IV experiments used the b-lacta-
mase reporter assay, whereas the Group III strain was tested by
an HPLC assay described below. The truncated Group II AIP
had no detectable activation activity for the four groups. Fur-
thermore, the peptide was an inhibitor in the nanomolar range
of the agr response in all four groups (Table 2), indicating that
deletion of the tail region of the peptide does indeed convert the
AIP from an agonist into an antagonist of self activation as well
as retaining intergroup inhibition.
The b-lactamase reporter assay could not be used for Group
III, because of the production of b-lactamase by all of the
available strains. However, we were able to demonstrate inhi-
bition of Group III S. aureus by the full-length and truncated
Group II AIP by HPLC analysis of d2toxin production (13).
d2Toxin is a ’25-aa hemolytic peptide encoded by RNAIII, and
the level of this translation product is proportional to the level
of RNAIII in the cell (13). Early exponential-phase cultures were
treated with increasing concentrations of truncated Group II
AIP and then allowed to grow for 9 h. Supernatants were
collected and the amounts of d2toxin quantitated. Inhibition by
the full-length Group II AIP was demonstrated with an IC50
value of 17 6 13 nM. A representative curve for inhibition by the
truncated Group II AIP is shown in Fig. 4, with an IC50 value of
10 6 1 nM (Table 2).
The truncated thiolactone peptide is therefore a potent in-
hibitor for all four agr specificity groups of S. aureus. We have
also begun to test the activity of AIPs in alternative staphylo-
coccal species by using HPLC analysis of d2toxin production.
Our preliminary results thus far show only weak inhibition (in the
micromolar range) of S. epidermidis strain RN2375 by the
full-length and truncated group II AIPs. However, strong inhi-
bition (in the nanomolar range) by the truncated group II AIP
was seen with the S. warnerii strain RN3178, with an IC50 value
of 20 6 12 nM.
Discussion
Two-component systems are the major means by which bacteria
sense a large variety of environmental stimuli. In most cases, the
activating ligands for the receptors are unknown (17). The agr
system is one of a few cases where the ligands have been
chemically characterized, as thiolactone peptides (AIPs), and the
system is unique in that AIPs from heterologous strains are
naturally occurring inhibitors of agr signaling. In this study, we
have begun to analyze the mechanism by which naturally occur-
ring AIP sequence variants inhibit agr activation. Although the
agr locus is conserved throughout the staphylococci, the agr
autoinducing peptides and their cognate receptors have radically
diverged, generating at least four autoinduction specificity
groups in S. aureus. In general, the AIP activates agr expression
in strains belonging to the same group as the producing organism
and inhibits agr expression in organisms belonging to any other
group. It is very possible that this divergence causes intergroup
interference, leading to environmental isolation, and is at least
partially responsible for speciation within the staphylococci.
Similar divergence within the structurally similar comAP locus,
required for competence in Bacilli, is also thought to be respon-
sible for speciation in these organisms (18).
Structure–activity analysis has revealed two key features of the
AIP–receptor interaction in S. aureus that are critical for the
understanding of the present results: (i) Derivative peptides of
the Group II AIP with a lactone or lactam replacing the essential
thiolactone bond showed substantial loss of intragroup agr
activation activity (at least 100-fold less potent) but retention of
cross-inhibition activity. These derivatives, however, did not
inhibit activation of the cognate receptor by the native thiolac-
tone peptide (did not self inhibit). (ii) Substitution of any amino
acid residue within the C-terminal thiolactone ring affected
Fig. 4. The Group III strain, RN8465, was grown in the presence of differing
concentrations of the truncated Group II analog. A representative inhibition
curve derived from reversed-phase HPLC analysis of d2toxin levels is shown.
Quantitation of d2toxin levels was obtained by integration of peak area from
the HPLC trace.
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either activation andyor inhibition activity, whereas substitution
of any of the four residues in the N-terminal linear section of the
peptide decreased or eliminated activation but did not decrease
inhibition. We have previously hypothesized that activation and
inhibition by native AIPs must therefore involve different mech-
anisms—either different modes of interaction with the AIP
receptor, AgrC, or interaction with cellular components other
than AgrC, e.g., AgrB.
This latter possibility was clearly ruled out by means of plas-
mid constructs containing a b-lactamase reporter driven by
the (conserved) agr P3 promoter and including the P2 driven
agrA 1 C modules from different specificity groups. Placement
of these plasmids in agr-null derivatives of the agr specificity
group corresponding either to that of the cloned module or to
that of other groups enabled the direct in vivo analysis of
AIP-specific activationyinhibition in the absence of AgrB or of
any endogenous AIP. Because these tests demonstrated the
predicted cross-group inhibition, qualitatively in parallel with
previous results obtained with the endogenous agr loci intact, it
is clear that AgrB is not the site of inhibition. Since these tests
also demonstrated that crossgroup inhibition occurs indepen-
dently of host background, and with similar dose responses, it is
also clear that the only determinant of agr group specificity is the
AgrA 1 C module. Although we have not tested AgrA and C
independently, AgrA is highly conserved among agr specificity
groups within and between species, whereas the receptor portion
of AgrC is highly variable; thus there is little doubt that AgrC is
the key determinant. Although there are certainly other cellular
factors involved in agr signaling, our results indicate that none of
these determines group specificity.
The assay method used in this study is different from that
previously used (12), in enabling an assessment of AIP activity
in the absence of skewing effects of the endogenous peptide. The
values obtained here are a more accurate reflection of the
correct physiological values, because we can precisely deliver and
quantify the amount of AIP in the system. The inhibition studies
for the agr-null Group I and II strains reconstituted with the
AgrA 1 C modules were performed with activator at 100 nM,
which was determined to be a saturating but not oversaturating
dose of activator. This generated maximal activation against
which to test various concentrations of inhibiting heterologous
AIPs. This differs from the natural situation, where the concen-
tration of the endogenously produced peptide appears to be less
than 100 nM, on the basis of comparison of the measured IC50
values with those of a previous study by using endogenously
produced peptide as the source of activator (12).
The apparent difference in the roles of the ring and tail
moieties of the Group II AIP could be interpreted to mean that
the ring structure is responsible for recognition of and binding
to the putative ligand pocket of the receptor, and that the tail
region is responsible for initiating the signaling process. It was
reasoned that removal of the tail region might render a ligand
that should be unable to activate AgrC signaling but should be
a strong inhibitor of its cognate AgrC as well as of the heterol-
ogous AgrCs. This was confirmed by using a synthetic Group II
AIP lacking the tail but retaining the thiolactone structure. This
peptide inhibited not only the Group II receptor but also those
of Groups I, III, and IV (which, based on our current under-
standing of agr grouping, represents global agr inhibition in S.
aureus). Furthermore, the truncated analog weakly inhibited
d2toxin production in the S. epidermidis strain, RN2375, but
strongly inhibited d2toxin production in the S. warnerii strain,
RN3178. These results suggest that the truncated thiolactone
Group II AIP may serve as the model for a global inhibitor of
staphylococcal agr activation, which may have significant clinical
utility.
The observation that an AIP agonist of the agr response (i.e.,
the intragroup AIP) can be converted into an antagonist of that
response by removing the tail (i.e., the truncated AIP) provides
further compelling evidence that AgrC is the molecular locus of
activation and inhibition. These results also suggest that other
less dramatic modifications in the AIP tail might lead to the
generation of global inhibitors of the agr response. Several
questions remain to be answered in this system. For example, we
have yet to fully account for why the lactam and lactone Group
II AIP analogs are potent intergroup inhibitors but are not
potent self activators or inhibitors. Clearly, this points to the
thiolactone linkage being an important determinant of self
activation or inhibition. We have previously speculated that the
acylating nature of the thioester group might play a role in these
processes and, although the current study does not address this
issue specifically, it does identify AgrC as the likely target of such
a modification, should it take place. Future studies will now
address this issue, as well as whether activation and inhibition
occur within the same binding pocket of AgrC.
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